Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRA NYSE:JATT NASDAQ:MAAQ NASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.47+1.8%$3.27$2.08▼$10.16$8.84M0.26643,273 shs52,759 shsJATTJATT Acquisition$1.99+13.7%$1.40$7.80▼$12.38$34.33MN/A41,322 shs837,649 shsMAAQMana Capital Acquisition$3.64+4.0%$3.93$5.35▼$10.25$29.58MN/A33,075 shs4,513 shsMURAMural Oncology$2.08+0.5%$2.27$0.95▼$4.74$36.03M31.99 million shs435,374 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica+6.23%-2.85%-5.28%+9.65%-2.08%JATTJATT Acquisition+1.16%+10.06%+1.74%+68.27%-50.70%MAAQMana Capital Acquisition-4.63%-6.42%-18.60%-17.45%+677.95%MURAMural Oncology-0.96%+16.95%-15.51%-24.73%-37.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica0.8367 of 5 stars0.05.00.00.02.00.80.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology2.9824 of 5 stars3.33.00.00.01.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/AMAAQMana Capital Acquisition 0.00N/AN/AN/AMURAMural Oncology 2.50Moderate Buy$12.00478.31% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.68M1.56N/AN/A$3.13 per share1.11JATTJATT AcquisitionN/AN/A$0.07 per share27.08($0.53) per shareN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/A$3.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/27/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%N/ALatest BMRA, MURA, MAAQ, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.762.76JATTJATT AcquisitionN/A0.150.15MAAQMana Capital AcquisitionN/AN/AN/AMURAMural OncologyN/A2.872.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%JATTJATT Acquisition47.97%MAAQMana Capital Acquisition68.44%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%JATTJATT Acquisition20.00%MAAQMana Capital AcquisitionN/AMURAMural Oncology2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million2.16 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMURAMural Oncology11917.32 million16.94 millionOptionableBMRA, MURA, MAAQ, and JATT HeadlinesRecent News About These CompaniesAdvising XOMA Royalty on its Acquisition of Mural OncologyAugust 22 at 7:50 AM | mhc.ieMXOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash TransactionAugust 22 at 2:50 AM | pharmexec.comPMural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cashAugust 20 at 7:18 PM | msn.comXoma, a drug royalty specialist, buys another ‘zombie’ biotechAugust 20 at 7:18 PM | finance.yahoo.comMURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to ShareholdersAugust 20 at 10:40 AM | businesswire.comMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20 at 8:30 AM | globenewswire.comTwo new murals installed in Downtown PeoriaAugust 19 at 6:16 PM | msn.comFrom courtyard to connection: KGH welcomes a new healing muralAugust 19 at 6:16 PM | interiorhealth.caIWhy some in Columbia cared so much about saving Hunter-Gatherer’s bricks & muralAugust 14, 2025 | thestate.comTMural Oncology (MURA) to Release Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comColourful mural celebrates 10 years of cancer care at WWLAugust 4, 2025 | msn.comMural Oncology Announces Second Quarter Financial Results and Provides Business UpdateAugust 4, 2025 | globenewswire.comArtists help pupils and centre users create muralsAugust 3, 2025 | msn.comBaltimore honors Henrietta Lacks with community-painted muralAugust 2, 2025 | msn.comBaltimore community comes together to complete Henrietta Lacks muralAugust 2, 2025 | wmar2news.comWCommunity news: Mural walk, health fair, digital skill lessonsJuly 28, 2025 | chicagotribune.comDowntown Raleigh’s history unfolds in a sprawling new mural. Who is on it?July 28, 2025 | msn.comNew mural inspires student growth on the Eastern ShoreJuly 28, 2025 | msn.comCan Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?July 23, 2025 | finance.yahoo.comMinneapolis muralist honors Tuskegee airmenJuly 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMRA, MURA, MAAQ, and JATT Company DescriptionsBiomerica NASDAQ:BMRA$3.47 +0.06 (+1.76%) Closing price 04:00 PM EasternExtended Trading$3.42 -0.05 (-1.30%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.JATT Acquisition NYSE:JATT$1.99 +0.24 (+13.71%) As of 08/21/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Mana Capital Acquisition NASDAQ:MAAQ$3.64 +0.14 (+4.00%) As of 08/21/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Mural Oncology NASDAQ:MURA$2.08 +0.01 (+0.48%) Closing price 04:00 PM EasternExtended Trading$2.07 -0.01 (-0.48%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.